Eli Lilly and Company (NYSE: LLY) is a titan of the pharmaceutical industry, a position bolstered by the monumental success of its GLP-1 diabetes and obesity drug franchise. With products like ...
FILE PHOTO: A box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly is seen at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey ...
FILE PHOTO: Wegovy injector pen boxes are displayed at the Novo Nordisk booth at the China Obesity Congress 2025 (COC2025) in Beijing, China August 17, 2025. REUTERS/Andrew Silver/File Photo Dec 29 ...
SHANGHAI, Dec 8 (Reuters) – Eli Lilly and Co.’s popular drug Mounjaro will be added to China’s state-run health insurance scheme from Jan. 1 for patients with type 2 diabetes, the National Healthcare ...
Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health ...
Eli Lilly and Company (NYSE:LLY) is one of the most profitable blue chip stocks to invest in now. Reuters reported on March 11 that Eli Lilly and Company (NYSE:LLY) plans to invest $3 billion in China ...
Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs. The two companies have worked together since 2023. Insilico's CEO, Alex Zhavoronkov, ...
The China Diabetes Devices Market is projected to grow from USD 7.19 billion in 2025 to USD 14.51 billion by 2034, marking a ...
24/7 Wall St. on MSN
Is Eli Lilly going to $1,100?
Quick Read Eli Lilly (LLY) reported Q1 2026 revenue of $19.799B, beating consensus by 11.25% with 56% YoY growth, while ...
SHANGHAI, Dec 8 (Reuters) - Eli Lilly's popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with type 2 diabetes, the National Healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results